Preferred Label : MALT1 Inhibitor SGR-1505;
NCIt definition : An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation
protein 1 (MALT1), with potential immunomodulating and antineoplastic activities.
Upon oral administration, MALT1 inhibitor SGR-1505 targets, binds to, and inhibits
the activity of MALT1. This inhibits MALT1-dependent CARD11-BCL10-MALT1 (CBM) signaling,
thereby inhibiting the immunosuppressive function of regulatory T-cells (Tregs) and
upregulating the production of interferon-gamma (IFN-g) by Tregs in the tumor microenvironment
(TME). This results in the inhibition of Janus kinase/signal transducers and activators
of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling,
induces apoptosis, and inhibits tumor cell growth. MALT1 belongs to the caspase family
of proteases and is the active component of the CBM signaling complex. It plays an
essential role in mediating the immunosuppressive activities of Tregs, and is overactivated
in certain tumor cells, including non-Hodgkin B-cell lymphomas.;
Molecule name : SGR 1505; SGR-1505;
NCI Metathesaurus CUI : CL1905135;
Origin ID : C191831;
UMLS CUI : C5784738;
Semantic type(s)
- concept_is_in_subset
- has_target
